JP Morgan Chase’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-1,400
Closed -$420K – 7764
2024
Q3
$420K Hold
1,400
– – ﹤0.01% 5014
2024
Q2
$461K Sell
1,400
-5,000
-78% -$1.77M ﹤0.01% 4736
2024
Q1
$2.53M Buy
6,400
+5,000
+357% +$1.85M ﹤0.01% 3657
2023
Q4
$493K Sell
1,400
-45,500
-97% -$16.1M ﹤0.01% 4807
2023
Q3
$17.6M Buy
+46,900
New +$18.1M ﹤0.01% 1783
2022
Q3
– Sell
-24,000
Closed -$7.26M – 6898
2022
Q2
$7.26M Buy
+24,000
New +$7.81M ﹤0.01% 2434

Other funds holding WST

JP Morgan Chase's WST Position: Q2 2026 in Review

JP Morgan Chase increased its West Pharmaceutical (WST) stake by 12% in Q2 2026, buying an estimated $37M and bringing the position to 1,164,527 shares worth $413M. The position accounts for 0.02% of the portfolio, ranked #506.

JP Morgan Chase first reported a position in WST in Q2 2013 and has held it in 53 quarters since. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • JP Morgan Chase held 1,164,527 shares of West Pharmaceutical worth $413M as of Q2 2026.
  • JP Morgan Chase bought 121,110 West Pharmaceutical shares in Q2 2026, an estimated $37M.
  • West Pharmaceutical made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #506 holding.
  • JP Morgan Chase first reported a position in West Pharmaceutical in Q2 2013 and has held it in 53 quarters since.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.